Current management of hepatocellular carcinoma: An Eastern perspective

Table 2 Randomized controlled trials with molecular target therapies[92]

	Status
First line
Comparison with placebo
Sorafenib (SHARP, Asian-Pacific)	Proven benefit
Sorafenib in Child B (BOOST)	Phase III Ongoing
Comparison study between sorafenib and single agent (head to head)
Sunitinib -> endpoint not met	Terminated
Brivanib (BRISK-FL) -> endpoint not met	Failed
Linifanib -> endpoint not met	Terminated
Lenvatinib	Phase III ongoing
Combination of sorafenib and another agent
Sorafenib + Erlotinib (SEARCH) -> endpoint not met	Failed
Sorafenib + Doxorubicin (CALGB-80802)	Phase III ongoing
Sorafenib + Everolimus	R-Phase II; Failed
Second line
Sorafenib failure
Brivanib (BRISK-PS) -> endpoint not met	Failed
Brivanib (BRISK-APS)	Terminated
Everolimus (EVOLVE-1) -> endpoint not met	Failed
Ramucirumab (REACH)	Phase III ongoing
Regorafenib (RESORCE)	Phase III ongoing
Cabozantinib (CELESTAL)	Phase III ongoing
Tivantinib (Metiv-HCC)	Phase III ongoing
Combination or addition to standard therapies
Adjuvant setting after surgery or RFA: Sorafenib (STORM)
	Failed
Combination with TACE: Sorafenib (SPACE) -> endpoint not met
	Failed
Brivanib (BRISK-TA) -> endpoint not met	Failed
Sorafenib (TACTICS)	R-Phase II ongoing

RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization.